ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been
This is the first time that a multinational pharmaceutical company has gained exclusive authorization in China to promote an innovative drug independently developed by a Chinese pharmaceutical company.
Through the investment, Schott plans to expand its primary business of glass tubing, used as the starting material for pharmaceutical packaging, and also pharmaceutical packaging made of glass and
The designation to SLN124 was granted by the Committee for Orphan Medicinal Products (COMP), a committee of the European Medicines Agency (EMA). COMP after reviewing an application filed
HCC is the most common form of liver cancer and the fastest-rising cause of cancer-related death in the U.S. “This new indication for CABOMETYX is an important treatment
The pharma giant filed two new drug applications (NDAs) with the regulator covering the two forms of tafamidis – meglumine salt and free acid. The company said that
US 10,166,194, entitled “Hydrocortisone Controlled Release Formulation”, is a patent claiming a method of treatment for adrenal dysfunction, including the diseases congenital adrenal hyperplasia (CAH) and adrenal insufficiency
Under the new CLAs, Agenus will leverage Selexis’ modular SUREtechnology Platform for the rapid, stable, and cost-effective production of its therapeutic proteins. Selexis licensing and business development vice
The cash-cum-stock deal between Takeda and Shire was signed in May 2018 in a move to create a global, values-based research and development (R&D) driven biopharma company headquartered
These new candidates target rare genetic chronic diseases. According to the agreement, CANbridge has an exclusive regional or global rights for these therapies. WuXi Biologics will receive upfront,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.